Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase - Should You Buy?

Genmab A/S (NASDAQ:GMAB - Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 4,599,016 shares were traded during mid-day trading, an increase of 203% from the previous session's volume of 1,518,271 shares.The stock last traded at $19.79 and had previously closed at $19.58.

Analysts Set New Price Targets

A number of brokerages have weighed in on GMAB. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Redburn Atlantic started coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a "buy" rating on the stock. Finally, BMO Capital Markets reiterated an "outperform" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $45.20.

Genmab A/S Price Performance

The company has a fifty day moving average price of $21.07 and a 200 day moving average price of $23.82. The stock has a market cap of $13.11 billion, a P/E ratio of 19.24, a P/E/G ratio of 0.57 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same quarter last year, the firm posted $0.47 EPS. As a group, sell-side analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. Blue Trust Inc. raised its position in Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock valued at $108,000 after buying an additional 3,880 shares during the last quarter. R Squared Ltd bought a new position in Genmab A/S during the 4th quarter valued at $93,000. Allspring Global Investments Holdings LLC boosted its holdings in Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock worth $113,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC bought a new stake in shares of Genmab A/S in the 3rd quarter worth $192,000. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.